RxDoctor Payments Data

Deepa Diaram

Podiatrist · Seaford, DENPI 1083994305

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Smith+Nephew at 53.2% of the total. Reporting peaked in 2019 at $376 and has fallen 95.1% since, to $18 in 2025. That places this record below the midpoint for podiatrist clinicians in DE, where the typical reported total is $1,099.

$763in general payments, 2019–2025

Across 54 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$406
  • Osiris Therapeutics Inc.$82
  • Integra Lifesciences Corporation$46
  • Kerecis Limited$37
  • Organogenesis Inc.$32
  • Medela LLC$29
  • plus $131 from 7 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 40th percentile of 37 podiatrist providers in Delaware.

See all podiatrist providers in Delaware

Medicare billing

Part B allowed, 2024
$184,017
Medicare patients
523
Services billed
2,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox36$772
Ketoconazole32$646
Terbinafine Hcl19$428
Ammonium Lactate16$364
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$349
Gabapentin38$321
Methylprednisolone18$103
Doxycycline Hyclate15$71
Cephalexin17$60

Paid to pharmacies, not to this prescriber.

Other podiatrist in Seaford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →